Market Overview

PTC Therapeutics Moves On Old Report

PTC Therapeutics Moves On Old Report

PTC Therapeutics, Inc. (NASDAQ: PTCT) plunged as low as 4 percent off Thursday’s highs as traders circulated a report citing termination of the firm’s 2A ataluren study for Duchenne and Becker muscular dystrophies. However, a company spokesperson clarified that this was “very old news.”

“The Phase 3 was completed almost two years ago,” the representative told Benzinga. PTC recently filed a New Drug Application with the Food and Drug Administration for ataluren for the treatment of Duchenne Muscular Dystrophy and has an expected Prescription Drug User Fee Act date of Oct. 24.

The government record that seemingly concerned traders was last updated Tuesday for unknown reasons, and the edit alert may have triggered alarm.

PTC shares recovered and were trading above opening rates at the time of publication.

Related BZ Pro Headlines:

PTC Therpapeutics Spokesperson Tells Benzinga 'This is Very Old News...Phase 3 was Completed Almost Two Years Ago'

PTC Study Of Ataluren Has Been Terminated


Related Articles (PTCT)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care FDA Events Exclusives Movers Interview Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at